← All trials
NCT05188378
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2021
- Primary completion
- Oct 1, 2022
- Completion date
- Jan 31, 2023
- First posted
- Jan 12, 2022
- Last posted
- Jan 12, 2022
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelltrionLead sponsor
- Gachon UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Jeonbuk National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.